More accurate and quantitative measurement of lower HER2 expression levels may also be helpful for ongoing and planned trials of new anti-HER2 therapies, such as investigational anti-HER2 monoclonal antibodies such as margetuximab and anti-HER2 vaccines targeting HER2 non-overexpressing breast cancer patients [22-24]. The gene discussed is ERBB2; the disease is breast cancer.